Furthermore, in melanoma, sargramostim and ipilimumab combination therapy increased overall survival (OS) and enhanced expression of inducible T-cell co-stimulator (ICOS) on CD4+ and CD8+ T cells over ipilimumab alone (28). This evidence concerns the gene CD4 and melanoma.